Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Feb 26:11:407-15.
doi: 10.2147/COPD.S91118. eCollection 2016.

A cross-sectional study to assess inhalation device handling and patient satisfaction in COPD

Marc Miravitlles  1 , Jéssica Montero-Caballero  2 , Frank Richard  2 , Salud Santos  3 , Juan Luis Garcia-Rivero  4 , Francisco Ortega  5 , Xavier Ribera  6
Affiliations

A cross-sectional study to assess inhalation device handling and patient satisfaction in COPD

Marc Miravitlles et al. Int J Chron Obstruct Pulmon Dis. .

Abstract

Delivery of inhaled medications via an inhaler device underpins the effectiveness of treatment for patients with chronic obstructive pulmonary disease (COPD). Correct inhaler technique among patients is also a predictor of achieving treatment compliance and adherence. Reporting of patient satisfaction with inhalers is therefore gaining increasing attention and is now recognized as an important patient-reported outcome in clinical trials involving patients with COPD or asthma. In this cross-sectional study, we use the validated Patient Satisfaction and Preference Questionnaire (PASAPQ) to assess the handling and satisfaction for Respimat(®) Soft Mist™ Inhaler (SMI) compared with the Breezhaler(®) dry powder inhaler (DPI) among patients with COPD in Spain. Patients were already assigned to therapy with either SPIRIVA(®) (tiotropium) Respimat(®) or with Hirobriz(®)/Onbrez(®)/Oslif(®) (indacaterol) Breezhaler(®) for at least 3 but not more than 6 months before completing the PASAPQ at a single visit to the study site. The primary endpoint of the trial was the mean total PASAPQ score. Secondary endpoints were the performance score domain of the PASAPQ, the convenience score domain of the PASAPQ, and the overall satisfaction score of the PASAPQ. For the primary endpoint, the mean PASAPQ total score in the Respimat(®) and Breezhaler(®) groups was 80.7 and 79.9, respectively (difference of 0.8, 95% confidence interval [CI] -2.9 to 4.5; P=0.67). The mean total performance scores were 82.5 and 78.2 (difference of 4.3, 95% CI -0.3 to 8.9; P=0.06), and the mean total convenience scores were 78.6 and 81.9 (difference of -3.3, 95% CI -7.0 to 0.4; P=0.08) for the Respimat(®) and Breezhaler(®) groups, respectively. Patients gave the Respimat(®) SMI and the Breezhaler(®) DPI overall satisfaction PASAPQ scores of 6.0 and 5.9, respectively, which shows that patients were satisfied with these inhalers.

Keywords: Breezhaler®; COPD; Respimat®; handling; inhaler.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mean PASAPQ scores by treatment. Abbreviations: PASAPQ, Patient Satisfaction and Preference Questionnaire; SD, standard deviation.
Figure 2
Figure 2
Distribution of total PASAPQ scores. Abbreviation: PASAPQ, Patient Satisfaction and Preference Questionnaire.
See this image and copyright information in PMC

References

    1. Moroni-Zentgraf P. Impact of patient needs on design and usage of an inhalation device in respiratory medicine. Respir Drug Deliv Eur. 2013;1:141–152.
    1. Virchow JC, Crompton GK, Dal NR, et al. Importance of inhaler devices in the management of airway disease. Respir Med. 2008;102(1):10–19. - PubMed
    1. Lavorini F, Magnan A, Dubus JC, et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med. 2008;102(4):593–604. - PubMed
    1. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–497. - PubMed
    1. Molimard M. How to achieve good compliance and adherence with inhalation therapy. Curr Med Res Opin. 2005;21(Suppl 4):S33–S37. - PubMed

MeSH terms